Mylan Says Cephalon's IP Win Based On Wrong Construction
Mylan Pharmaceuticals Inc. on Friday urged the Federal Circuit to reverse a district court's ruling that it infringed three patents for Cephalon Inc.'s cancer painkiller Fentora, saying the lower court failed to use...To view the full article, register now.
Already a subscriber? Click here to view full article